📊 SGMO Key Takeaways
Is Sangamo Therapeutics, Inc. (SGMO) a Good Investment?
Sangamo faces imminent solvency and liquidity crises with negative stockholders' equity of -$19.0M, current ratio of 0.70x, and annual operating cash burn of $19.3M against only $27.6M in cash reserves, providing approximately 17 months of runway. Revenue has collapsed 31.6% YoY to just $1.4M while net losses remain massive at -$31.0M, indicating a development-stage company unable to generate meaningful commercial traction and facing existential funding pressure.
Sangamo Therapeutics, Inc. Key Strengths (SGMO)
- Remaining cash buffer of $27.6M provides near-term runway
- Net losses improving YoY (-25.5% improvement in net income), suggesting cost management progress
- 12 Form 4 insider filings in 90 days indicates ongoing executive engagement
SGMO Stock Risks: Sangamo Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$19.0M indicates technical insolvency and negative book value
- Current ratio of 0.70x signals acute liquidity stress with current liabilities exceeding liquid assets
- Operating cash burn of -$19.3M annually with only ~17 months of cash runway before depletion
- Revenue collapsing 31.6% YoY to $1.4M shows commercial failure and lack of market traction
- Operating margin of -2215% and net margin of -2149% indicate unsustainable unit economics
- No visible path to profitability; company dependent on capital raises or strategic transactions for survival
Key Metrics to Watch
- Quarterly cash balance trend and burn rate acceleration/deceleration
- Revenue stabilization or recovery trajectory YoY
- Gross margin emergence if revenue scales, and operating expense reduction rate
Sangamo Therapeutics, Inc. (SGMO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SGMO Profit Margin, ROE & Profitability Analysis
SGMO vs Healthcare Sector: How Sangamo Therapeutics, Inc. Compares
How Sangamo Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sangamo Therapeutics, Inc. Stock Overvalued? SGMO Valuation Analysis 2026
Based on fundamental analysis, Sangamo Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sangamo Therapeutics, Inc. Balance Sheet: SGMO Debt, Cash & Liquidity
SGMO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sangamo Therapeutics, Inc.'s revenue has declined by 51% over the 5-year period, indicating business contraction. The most recent EPS of $-0.49 indicates the company is currently unprofitable.
SGMO Revenue Growth, EPS Growth & YoY Performance
SGMO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.4M | -$30.6M | $-0.08 |
| Q3 2025 | $581.0K | $10.7M | $0.04 |
| Q2 2025 | $356.0K | -$20.0M | $-0.08 |
| Q1 2025 | $481.0K | -$30.6M | $-0.14 |
| Q3 2024 | $9.4M | $10.7M | $0.04 |
| Q2 2024 | $356.0K | -$36.1M | $-0.18 |
| Q1 2024 | $481.0K | $21.1M | $0.12 |
| Q3 2023 | $9.4M | -$53.2M | $-0.34 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sangamo Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SGMO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sangamo Therapeutics, Inc. (CIK: 0001001233)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 27, 2026 | 4 | xslF345X06/form4-05272026_070509.xml | View → |
| May 27, 2026 | 4 | xslF345X06/form4-05272026_070507.xml | View → |
| May 27, 2026 | 4 | xslF345X06/form4-05272026_070505.xml | View → |
| May 27, 2026 | 4 | xslF345X06/form4-05272026_070504.xml | View → |
| May 27, 2026 | 4 | xslF345X06/form4-05272026_070501.xml | View → |
❓ Frequently Asked Questions about SGMO
What is the AI rating for SGMO?
Sangamo Therapeutics, Inc. (SGMO) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SGMO's key strengths?
Claude: Remaining cash buffer of $27.6M provides near-term runway. Net losses improving YoY (-25.5% improvement in net income), suggesting cost management progress.
What are the risks of investing in SGMO?
Claude: Negative stockholders' equity of -$19.0M indicates technical insolvency and negative book value. Current ratio of 0.70x signals acute liquidity stress with current liabilities exceeding liquid assets.
What is SGMO's revenue and growth?
Sangamo Therapeutics, Inc. reported revenue of $1.4M.
Does SGMO pay dividends?
Sangamo Therapeutics, Inc. does not currently pay dividends.
Where can I find SGMO SEC filings?
Official SEC filings for Sangamo Therapeutics, Inc. (CIK: 0001001233) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SGMO's EPS?
Sangamo Therapeutics, Inc. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SGMO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Sangamo Therapeutics, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SGMO stock overvalued or undervalued?
Valuation metrics for SGMO: ROE of N/A (sector avg: 15%), net margin of -2,149.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SGMO's AI grade for 2026?
Our dual AI analysis gives Sangamo Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SGMO's free cash flow?
Sangamo Therapeutics, Inc.'s operating cash flow is $-19.3M, with capital expenditures of $13.0K. FCF margin is -1,338.1%.
How does SGMO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,149.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.70 (avg: 2).